Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Elizabeth A. Poplin, MD
Rutgers Cancer Institute of New Jersey
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
- Centrastate Medical Center
Freehold, New Jersey, United States
- Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States
- Jersey Shore Cancer Center at Jersey Shore University Medical Center
Neptune City, New Jersey, United States
- Cancer Institute of New Jersey at Umdnj - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
- Central Jersey Oncology Group
New Brunswick, New Jersey, United States
- Saint Peter'S University Hospital
New Brunswick, New Jersey, United States
- New Jersey Medical School
Newark, New Jersey, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2005
- Primary completion
- 31 Oct 2010
- Completion
- 31 Oct 2010
- Last update posted
- 14 Aug 2023
- Registered enrollment
- 44
- Registry id
- NCT00161213
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.